Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07136181 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
A Phase 1 study of Metastatic Uveal Melanoma and Eye Cancer, sponsored by Novelwise Pharmaceutical Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT07136181 is a Phase 1 study of Metastatic Uveal Melanoma and Eye Cancer that is actively recruiting participants, run by Novelwise Pharmaceutical Corporation. The registered enrollment target is 36 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07136181, a Phase 1 study of Metastatic Uveal Melanoma and Eye Cancer, is actively recruiting participants, sponsored by Novelwise Pharmaceutical Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study will help doctors learn about the side effects of NBM-BMX, how the drug is processed in the body, and whether it may slow down or shrink tumors. Participants will take NBM-BMX as a capsule by mouth twice daily on an empty stomach with at least six ounces (180 mL) of water. No food or drink (other than water) should be consumed for at least two hours after each dose. Participants will visit the clinic about once every week or two for exams and blood tests while taking NBM-BMX. After stopping treatment, a follow-up visit will occur about 30 days later. Treatment may continue as long as the cancer does not get worse and side effects remain manageable.
Conditions Studied
Interventions
- DRUG NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Study Locations (3)
Arizona
- Honor Health Resarch Institute - Scottsdale
Colorado
- Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location - Denver
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07136181
The ClinicalTrials.gov registry entry for NCT07136181 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (72% lower). The listed sponsor is Novelwise Pharmaceutical Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. is the first listed.
NCT07136181 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07136181 about?
NCT07136181 is a clinical study titled "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma". This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study will help doctors learn about the side effects of NBM-BMX, how the drug is processed in the ...
What is the current status of trial NCT07136181?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-11-20. Estimated completion is 2029-08-30.
What conditions does trial NCT07136181 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Eye Cancer, Uveal Melanoma, Recurrent, Uveal Melanoma, Metastatic, Eye Cancer, Intraocular Melanoma.
What interventions are being tested in trial NCT07136181?
The interventions under investigation include: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. (DRUG).
Who is sponsoring clinical trial NCT07136181?
This trial is sponsored by Novelwise Pharmaceutical Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07136181 being conducted?
This trial has 3 study locations across Arizona, Colorado, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Tebentafusp-tebn With LDT in Metastatic UM
RECRUITING · Phase 1
-
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
ACTIVE NOT RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.